Research programme: melanocortin receptor antagonists - Taisho
Alternative Names: Anti-anxiety therapy - Taisho; MCL 0129Latest Information Update: 04 Oct 2013
At a glance
- Originator Taisho Pharmaceutical
- Class Piperazines
- Mechanism of Action Melanocortin type 4 receptor antagonists; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 04 Oct 2013 Discontinued - Preclinical for Anxiety disorders in Japan (unspecified route)
- 04 Oct 2013 Discontinued - Preclinical for Major depressive disorder in Japan (unspecified route)
- 31 Dec 2009 No development reported - Preclinical for Anxiety disorders in Japan (unspecified route)